Therapeutic potential of targeting glutamate receptors in Parkinson’s disease

Journal of Neural Transmission

Volumn 121, Issue 8, 2014, Pages 861-880

  Finlay, Clare ^a   Duty, Susan ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Akinesia; AMPA receptor; L DOPA induced dyskinesia; Metabotropic glutamate receptor; Neurodegeneration; NMDA receptor; Non motor symptoms

Indexed keywords

GLUTAMATE RECEPTOR; IONOTROPIC RECEPTOR; LEVODOPA; METABOTROPIC RECEPTOR; ANTIPARKINSON AGENT;

ANXIETY DISORDER; ARTICLE; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DYSKINESIA; HUMAN; IMPULSE CONTROL DISORDER; MOTOR DYSFUNCTION; NERVE DEGENERATION; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN TARGETING; ANIMAL; DYSKINESIA, DRUG-INDUCED; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; PARKINSON DISEASE; RECEPTORS, GLUTAMATE;

EID: 84925781042     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1176-4     Document Type: Article

References (237)

1. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 20(10):1255-1263. doi:10.1002/mds.20527
2. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E (2009) Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613-618. doi:10.1016/s14744422(09)70146-2
3. Abou-Sleiman PM, Healy DG, Wood NW (2004) Causes of Parkinson's disease: genetics of DJ-1. Cell Tissue Res 318(1):185-188. doi:10.1007/s00441-004-0922-6
4. Addex Therapeutics. Geneva S (21 Mar 2012) http://www.addexther apeutics.com/investors/press-releases/news-details/article/addexreports- positive-top-line-phase-iia-data-for-dipraglurant-1in-par kinsons-disease-levodopa-indu/. Accessed 3 Oct 2012
5. Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring WJ, Ellenbogen A, Jinnah HA, Kirby L, Leibowitz MT, Stewart RM, Tarsy D, Tetrud J, Stoch SA, Gottesdiener K, Wagner J (2009) Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J Clin Pharmacol 49(7):856-864. doi:10. 1177/0091270009336735
6. Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, Fernandez- Espinola S, Andbjer B, Leo G, Medhurst AD, Agnati LF, Fuxe K (2005) Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 1033(2):216-220. doi:10.1016/j.brainres.2004.11.040
7. Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, Hammers A, Brooks DJ (2011) Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 134(Pt 4):979-986. doi:10.1093/brain/awr028
8. Aicher SA, Sharma S, Pickel VM (1999) N-Methyl-D-aspartate receptors are present in vagal afferents and their dendritic targets in the nucleus tractus solitarius. Neuroscience 91(1):119-132
9. Alam M, Danysz W, Schmidt WJ, Dekundy A (2009) Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Toxicol Appl Pharmacol 240(2):198-207. doi:10.1016/j. taap.2009.07.010
10. Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42(4):733-738
11. Aleyasin H, Rousseaux MW, Phillips M, Kim RH, Bland RJ, Callaghan S, Slack RS, During MJ, Mak TW, Park DS (2007) The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc Natl Acad Sci USA 104(47):18748-18753. doi:10.1073/pnas.0709379104
12. Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE Jr, Witkin JM (2007) Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology 52(7): 1482-1487. doi:10.1016/j.neuropharm.2007.02.005
13. Ambrosi G, Armentero MT, Levandis G, Bramanti P, Nappi G, Blandini F (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Res Bull 82(1-2):29-38. doi:10.1016/j.brainresbull.2010.01.011
14. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P (1995) Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15(4):961-973
15. Armentero MT, Fancellu R, Nappi G, Bramanti P, Blandini F (2006) Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis 22(1):1-9. doi:10. 1016/j.nbd.2005.09.010
16. Austin PJ, Betts MJ, Broadstock M, O'Neill MJ, Mitchell SN, Duty S (2010) Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease. Br J Pharmacol 160(7):1741-1753. doi:10.1111/j.1476-5381.2010.00820.x
17. Ba M, Kong M, Yang H, Ma G, Lu G, Chen S, Liu Z (2006) Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and L-DOPAtreated rats. Neurochem Res 31(11):1337-1347. doi:10.1007/s11064-006-9177-9
18. Ba M, Kong M, Yu G, Sun X, Liu Z, Wang X (2011) GluR1 phosphorylation and persistent expression of levodopa-induced motor response alterations in the Hemi-Parkinsonian rat. Neurochem Res 36(6):1135-1144. doi:10.1007/s11064-011-0461-y
19. Banerjee B, Medda BK, Zheng Y, Miller H, Miranda A, Sengupta JN, Shaker R (2009) Alterations in N-methyl-D-aspartate receptor subunits in primary sensory neurons following acid-induced esophagitis in cats. Am J Physiol Gastrointest Liver Physiol 296:G66-G77. doi:10.1152/ajpgi.90419.2008
20. Battaglia G, Busceti CL, Pontarelli F, Biagioni F, Fornai F, Paparelli A, Bruno V, Ruggieri S, Nicoletti F (2003) Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45(2):155-166
21. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, Fornai F, Nicoletti F, Bruno V (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in mice. J Neurosci 24(4):828-835. doi:10. 1523/jneurosci.3831-03.2004
22. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Traficante A, Nicoletti F, Bruno V (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J Neurosci 26(27):7222-7229. doi:10.1523/jneurosci.1595-06.2006
23. Battaglia G, Molinaro G, Riozzi B, Storto M, Busceti CL, Spinsanti P, Bucci D, Di Liberto V, Mudo G, Corti C, Corsi M, Nicoletti F, Belluardo N, Bruno V (2009) Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. PLoS ONE 4(8):e6591. doi:10.1371/journal.pone.0006591
24. Bennouar KE, Uberti MA, Melon C, Bacolod MD, Jimenez HN, Cajina M, Kerkerian-Le Goff L, Doller D, Gubellini P (2013) Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology 66:158-169. doi:10.1016/j.neuropharm.2012.03.022
25. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26(7):1243-1250. doi:10.1002/mds.23616
26. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354
27. Bermejo PE (2008) Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 14(5):448-449. doi:10.1016/j.parkreldis.2007.11.008
28. Betts MJ, O'Neill MJ, Duty S (2012) Allosteric modulation of the group III mGlu(4) receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease. Br J Pharmacol 166(8):2317-2330. doi:10.1111/j.1476-5381.2012. 01943.x
29. Beurrier C, Lopez S, Revy D, Selvam C, Goudet C, Lherondel M, Gubellini P, Kerkerian-LeGoff L, Acher F, Pin JP, Amalric M (2009) Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 23(10): 3619-3628. doi:10.1096/fj.09-131789
30. Black KJ, Friedman JH (2006) Repetitive and impulsive behaviors in treated Parkinson disease. Neurology 67(7):1118-1119. doi:10. 1212/01.wnl.0000243252.71365.81
31. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN (1999) Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa- treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 290(3):1034-1040
32. Blandini F (2010) An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol 25(2):65-71
33. Blandini F, Porter RH, Greenamyre JT (1996) Glutamate and Parkinson's disease. Mol Neurobiol 12(1):73-94. doi:10.1007/bf02740748
34. Blandini F, Nappi G, Greenamyre JT (2001) Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol 49(4):525-529
35. Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O (2013) Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. Parkinsonism Relat Disord 19(5):548-552. doi:10.1016/j.parkreldis.2013.02.003
36. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22(13):5669-5678
37. Broadstock M, Austin PJ, Betts MJ, Duty S (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165(4b):1034-1045. doi:10.1111/j.1476-5381.2011.01515.x
38. Brouillet E, Beal MF (1993) NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. NeuroReport 4(4):387-390
39. Bruno V, Sureda FX, Storto M, Casabona G, Caruso A, Knopfel T, Kuhn R, Nicoletti F (1997) The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J Neurosci 17(6):1891-1897
40. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 9(11):1106-1117. doi:10.1016/s1474-4422(10)70218-0
41. Calon F, Morissette M, Ghribi O, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo T (2002) Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated monkeys following dopamine agonist treatment. Prog Neuro-Psychopharmacol Biol Psychiatry 26(1): 127-138
42. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2003) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14(3):404-416
43. Caraci F, Molinaro G, Battaglia G, Giuffrida ML, Riozzi B, Traficante A, Bruno V, Cannella M, Merlo S, Wang X, Heinz BA, Nisenbaum ES, Britton TC, Drago F, Sortino MA, Copani A, Nicoletti F (2011) Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol Pharmacol 79(3):618-626. doi:10.1124/mol.110.067488
44. Cenci MA, Lundblad M (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99(2):381-392. doi:10.1111/j.1471-4159.2006.04124.x
45. Chan P, Di Monte DA, Langston JW, Janson AM (1997) (?)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J Pharmacol Exp Ther 280(1):439-446
46. Chaplan SR, Malmberg AB, Yaksh TL (1997) Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther 280:829-838
47. Chatha BT, Bernard V, Streit P, Bolam JP (2000) Synaptic localization of ionotropic glutamate receptors in the rat substantia nigra. Neuroscience 101(4):1037-1051
48. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464-474. doi:10.1016/s1474-4422 (09)70068-7
49. Chen SR, Pan HL (2005) Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured rats. J Pharmacol Exp Ther 312(1):120-126. doi:10.1124/jpet.104.073817
50. Chen L, Liu J, Ali U, Gui ZH, Hou C, Fan LL, Wang Y, Wang T (2011) Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions. Brain Res Bull 84(3):215-223. doi:10.1016/j. brainresbull.2011.01.005
51. Ciccarelli R, Di Iorio P, Bruno V, Battaglia G, D'Alimonte I, D'Onofrio M, Nicoletti F, Caciagli F (1999) Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia 27(3):275-281
52. Collins S, Sigtermans MJ, Dahan A, Zuurmond WWA, Perez RSGM (2010) NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med 11:1726-1742
53. Conn PJ, Battaglia G, Marino MJ, Nicoletti F (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6(10):787-798. doi:10.1038/nrn1763
54. Corti C, Battaglia G, Molinaro G, Riozzi B, Pittaluga A, Corsi M, Mugnaini M, Nicoletti F, Bruno V (2007) The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci 27(31):8297-8308. doi:10.1523/jneurosci.1889-07.2007
55. Cuomo D, Martella G, Barabino E, Platania P, Vita D, Madeo G, Selvam C, Goudet C, Oueslati N, Pin JP, Acher F, Pisani A, Beurrier C, Melon C, Kerkerian-Le Goff L, Gubellini P (2009) Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J Neurochem 109(4):1096-1105. doi:10.1111/j.1471-4159.2009.06036.x
56. D'Alessandro PL, Corti C, Roth A, Ugolini A, Sava A, Montanari D, Bianchi F, Garland SL, Powney B, Koppe EL, Rocheville M, Osborne G, Perez P, de la Fuente J, De Los Frailes M, Smith PW, Branch C, Nash D, Watson SP (2010) The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2. Bioorg Med Chem Lett 20 (2):759-762. doi:10.1016/j.bmcl.2009.11.032
57. Dawson L, Chadha A, Megalou M, Duty S (2000) The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol 129(3):541-546. doi:10.1038/sj.bjp.0703105
58. DeLeonibus E, Manago F, Giordani F, Petrosino F, Lopez S, Oliverio A, Amalric M, Mele A (2009) Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology 34(3):729-738. doi:10.1038/npp.2008.129
59. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62(1):10-15
60. Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull 69(3):318-326. doi:10.1016/j.brainresbull.2005.12.009
61. Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND (2011) Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem 54(1):342-353. doi:10.1021/jm1012165
62. DiLiberto V, Bonomo A, Frinchi M, Belluardo N, Mudo G (2010) Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain. Neuroscience 165(3):863-873. doi:10.1016/j.neuroscience.2009.11.012
63. Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, Bishop C (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 229(2):288-299. doi:10. 1016/j.expneurol.2011.02.012
64. Duty S (2010) Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol 161(2):271-287. doi:10.1111/j.1476- 5381.2010.00882.x
65. Duty S, Jenner P (2011) Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164(4):1357-1391. doi:10.1111/j.1476-5381. 2011.01426.x
66. Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W (2010) Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord 25(7):896-905. doi:10.1002/mds.22974
67. Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladström A, Jones R (2010) Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:969-977. doi:10.1016/S1474-4422(10)70194-0
68. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32(6):804-812. doi:10.1002/ana.410320616
69. Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR (2011) Management of punding in Parkinson's disease: an open-label prospective study. J Neurol 258(4):656-660. doi:10.1007/s00415-010-5817-8
70. Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, Rorick- Kehn L, Overshiner CD, Rasmussen K, Chaney SF, Benvenga MJ, Li X, Marlow DL, Thompson LK, Luecke SK, Wafford KA, Seidel WF, Edgar DM, Quets AT, Felder CC, Wang X, Heinz BA, Nikolayev A, Kuo MS, Mayhugh D, Khilevich A, Zhang D, Ebert PJ, Eckstein JA, Ackermann BL, Swanson SP, Catlow JT, Dean RA, Jackson K, Tauscher-Wisniewski S, Marek GJ, Schkeryantz JM, Svensson KA (2011) N-(4-((2-(trifluoromethyl)- 3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1- methy l-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther 336(1):165-177. doi:10.1124/jpet.110.172957
71. Felts AS, Rodriguez AL, Morrison RD, Venable DF, Manka JT, Bates BS, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2013) Discovery of VU0409106: a negative allosteric modulator of mGlu with activity in a mouse model of anxiety. Bioorg Med Chem Lett. doi:10.1016/j.bmcl.2013.09.001
72. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318(1):173-185. doi:10.1124/jpet.106.102046
73. Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, Cattabeni F, Di Luca M, Calabresi P (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26(11):2914-2922. doi:10.1523/jneurosci.5326-05. 2006
74. Gardoni F, Sgobio C, Pendolino V, Calabresi P, Di Luca M, Picconi B (2012) Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging 33(9): 2138-2144. doi:10.1016/j.neurobiolaging.2011.06.019
75. Gerlach M, Gsell W, Kornhuber J, Jellinger K, Krieger V, Pantucek F, Vock R, Riederer P (1996) A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res 741(1-2):142-152
76. Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16(5):418-427
77. Goudet C, Chapuy E, Alloui A, Acher F, Pin JP, Eschalier A (2008) Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 137(1):112-124. doi:10.1016/j.pain.2007.08.020
78. Graham WC, Robertson RG, Sambrook MA, Crossman AR (1990) Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of Parkinsonism. Life Sci 47:PL-91-PL97
79. Gravius A, Dekundy A, Nagel J, More L, Pietraszek M, Danysz W (2008) Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. J Neural Transm 115(12):1609-1619. doi:10.1007/s00702-008-0098-4
80. Greco B, Lopez S, van der Putten H, Flor PJ, Amalric M (2010) Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J Pharmacol Exp Ther 332(3):1064-1071. doi:10.1124/jpet.109.162115
81. Gregoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist. L-DOPA-treated parkinsonian monkeys. Parkinsonism Relat Disord 17(4):270-276. doi:10.1016/j.parkreldis.2011.01.008
82. Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48(4):503-516. doi:10.1016/j.neu ropharm.2004.11.008
83. Hametner E, Seppi K, Poewe W (2010) The clinical spectrum of levodopa-induced motor complications. J Neurol 257(Suppl 2):S268-S275. doi:10.1007/s00415-010-5719-9
84. Hanagasi HA, Kaptanoglu G, Sahin HA, Emre M (2000) The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-DOPA. Mov Disord 15(5):1016-1017
85. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284(2):651-660
86. Helton TD, Otsuka T, Lee MC, Mu Y, Ehlers MD (2008) Pruning and loss of excitatory synapses by the parkin ubiquitin ligase. Proc Natl Acad Sci USA 105(49):19492-19497. doi:10.1073/pnas. 0802280105
87. Hirsch EC, Perier C, Orieux G, Francois C, Feger J, Yelnik J, Vila M, Levy R, Tolosa ES, Marin C, Trinidad Herrero M, Obeso JA, Agid Y (2000) Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci 23(10 Suppl):S78-S85
88. Ho YJ, Ho SC, Pawlak CR, Yeh KY (2011) Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia. Behav Brain Res 219(2):280-290. doi:10.1016/j.bbr.2011.01.028
89. Hölscher C, McGlinchey L, Rowan MJ (1996) L-AP4 (L-(?)-2-amino- 4-phosphonobutyric acid) induced impairment of spatial learning in the rat is antagonized by MAP4 ((S)-2-amino-2-methyl-4- phosphonobutanoic acid). Behav Brain Res 81(1-2):69-79
90. Hsieh M-H, Ho S-C, Yeh K-Y, Pawlak CR, Chang H-M, Ho Y-J, Lai T-J, Wu F-Y (2012a) Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTPinduced Parkinson's disease rat model. Pharmacol Biochem Behav 102(1):64-71. doi:10.1016/j.pbb.2012.03.022
91. Hsieh MH, Ho SC, Yeh KY, Pawlak CR, Chang HM, Ho YJ, Lai TJ, Wu FY (2012b) Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. Pharmacology, Biochemistry and Behaviour 102(1):64-71. doi:10.1016/j.pbb.2012.03.022
92. Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, Azad SC (2010) Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain 14(4):387-394. doi:10.1016/j.ejpain.2009.08.002
93. Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P (2005) Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur J Neurosci 21(12):3240-3250. doi:10.1111/j.1460-9568.2005.04169.x
94. Iravani MM, McCreary AC, Jenner P (2012) Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia. Parkinsonism Relat Disord 18(Suppl 1):S123-S125. doi:10.1016/s1353-8020(11)70038-4
95. Isaacson SH, Hauser RA (2009) Improving symptom control in early Parkinson's disease. Ther Adv Neurol Disord 2(6):29-41. doi:10.1177/1756285609339383
96. Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665-677. doi:10.1038/nrn2471
97. Jensen J, Lehmann A, Uvebrant A, Carlsson A, Jerndal G, Nilsson K, Frisby C, Blackshaw LA, Mattsson JP (2005) Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol 519(1-2):154-157. doi:10.1016/j.ejphar.2005.07.007
98. Jimenez-Jimenez FJ, Molina JA, Vargas C, Gomez P, Navarro JA, Benito-Leon J, Orti-Pareja M, Gasalla T, Cisneros E, Arenas J (1996) Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. J Neurol Sci 141(1-2):39-44
99. Johnson KA, Jones CK, Tantawy MN, Bubser M, Marvanova M, Ansari MS, Baldwin RM, Conn PJ, Niswender CM (2013) The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Neuropharmacology 66:187-195. doi:10. 1016/j.neuropharm.2012.03.029
100. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM (2010) Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl- 1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 333(3):865-873. doi:10. 1124/jpet.110.166629
101. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R, Bogenpohl J, Smith Y, Morrison R, Daniels JS, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. J Med Chem 54(21):7639-7647. doi:10.1021/jm200956q
102. Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM (2012) The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther 340(2):404-421. doi:10.1124/jpet.111.187443
103. Kanthasamy AG, Kanthasamy A, Matsumoto RR, Vu TQ, Truong DD (1997) Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease. Brain Res 759(1):1-8
104. Kawamata M, Omote K (1997) Involvement of increased excitatory amino acids and intracellular Ca2? concentration in the spinal dorsal horn in an animal model of neuropathic pain. Pain 68:85-96
105. Keywood C, Wakefield M, Tack J (2009) A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 58(9):1192-1199. doi:10.1136/gut.2008.162040
106. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann Neurol 28:539-546
107. Klockgether T, Turski L, Honore T, Zhang ZM, Gash DM, Kurlan R, Greenamyre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 30(5):717-723. doi:10. 1002/ana.410300513
108. Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P (2010) Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J Neurochem 114(2):499-511. doi:10.1111/j.1471-4159.2010.06776.x
109. Kobylecki C, Crossman AR, Ravenscroft P (2013) Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia. Exp Neurol 247:476-484. doi:10.1016/j.expneurol.2013.01.019
110. Konieczny J, Wardas J, Kuter K, Pilc A, Ossowska K (2007) The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience 145(2):611-620. doi:10.1016/j.neuroscience.2006.12.006
111. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54(8):1589-1595
112. Kuiper MA, Teerlink T, Visser JJ, Bergmans PL, Scheltens P, Wolters EC (2000) L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 107(2):183-189
113. Kumar R, Hauser RA, Mostillo J, Dronamraju N, Graf A, Merschhemke M, Kenney C (2013) Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Int J Neurosci. doi:10.3109/00207454.2013. 841685
114. Kupsch A, Loschmann PA, Sauer H, Arnold G, Renner P, Pufal D, Burg M, Wachtel H, ten Bruggencate G, Oertel WH (1992) Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res 592(1-2):74-83
115. Lange KW, Loschmann PA, Sofic E, Burg M, Horowski R, Kalveram KT, Wachtel H, Riederer P (1993) The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTPinduced degeneration in primates. Naunyn-Schmiedeberg's Arch Pharmacol 348(6):586-592
116. Lau A, Tymianski M (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460(2):525-542. doi:10.1007/s00424-010-0809-1
117. Lavreysen H, Langlois X, Ahnaou A, Drinkenburg W, te Riele P, Biesmans I, Van der Linden I, Peeters L, Megens A, Wintmolders C, Cid JM, Trabanco AA, Andres JI, Dautzenberg FM, Lutjens R, Macdonald G, Atack JR (2013) Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther 346(3):514-527. doi:10.1124/jpet.113.204990
118. Leaver KR, Allbutt HN, Creber NJ, Kassiou M, Henderson JM (2008) Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. Clin Exp Pharmacol Physiol 35(11):1388-1394. doi:10.1111/j.1440-1681.2008.05046.x
119. Lee MC, Ting KK, Adams S, Brew BJ, Chung R, Guillemin GJ (2010) Characterisation of the expression of NMDA receptors in human astrocytes. PLoS ONE 5(11):e14123. doi:10.1371/journal.pone.0014123
120. Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Mouradian MM, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D (2012) Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord 27(2):284-288. doi:10. 1002/mds.23983
121. Lehmann A, Brandén L (2001) Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog. Eur J Pharmacol 431:253-258
122. Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F (2008) Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 29(1):161-168. doi:10.1016/j.nbd.2007.08.011
123. Lindelof K, Bendtsen L (2009) Memantine for prophylaxis of chronic tension-type headache-a double-blind, randomized, crossover clinical trial. Cephalalgia : an international journal of headache 29(3):314-321. doi:10.1111/j.1468-2982.2008.01720.x
124. Litvinenko IV, Odinak MM, Mogil'naya VI, Perstnev SV (2010) Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neurosci Behav Physiol 40(2):149-155
125. Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M (2007) Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J Neurosci 27(25):6701-6711. doi:10. 1523/jneurosci.0299-07.2007
126. Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P, Amalric M (2008) Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology 55(4):483-490. doi:10.1016/j.neuropharm.2008.06.038
127. Lopez S, Bonito-Oliva A, Pallottino S, Acher F, Fisone G (2011) Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease. J Parkinsons Dis 1(4):339-346. doi:10.3233/jpd-2011- 11066
128. Loschmann PA, Lange KW, Kunow M, Rettig KJ, Jahnig P, Honore T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDAantagonist CPP with L-DOPA in models of Parkinson's disease. J Neural Transm 3(3):203-213
129. Loschmann PA, De Groote C, Smith L, Wullner U, Fischer G, Kemp JA, Jenner P, Klockgether T (2004) Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 187(1):86-93. doi:10.1016/j.expneurol.2004.01.018
130. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, Agid Y, Brice A (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. New Engl J Med 342(21): 1560-1567. doi:10.1056/nejm200005253422103
131. Luginger E, Wenning GK, Bosch S, Poewe W (2000) Beneficial effects of amantadine on L-DOPA-induced dyskinesias in Parkinson's disease. Mov Disord 15(5):873-878
132. Luquin MR, Obeso JA, Laguna J, Guillen J, Martinez-Lage JM (1993) The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol 235(2-3):297-300
133. MacInnes N, Messenger MJ, Duty S (2004) Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol 141(1):15-22. doi:10.1038/sj.bjp.0705566
134. Maeda S, Kawamoto A, Yatani Y, Shirakawa H, Nakagawa T, Kaneko S (2008) Gene transfer of GLT-1, a glial glutamate transporter, into the spinal cord by recombinant adenovirus attenuates inflammatory and neuropathic pain in rats. Mol Pain 4:65. doi:10.1186/1744-8069-4-65
135. Makaroff L, Gunn A, Gervasoni C, Richy F (2011) Gastrointestinal disorders in Parkinson's disease: prevalence and health outcomes in a US claims database. J Parkinsons Dis 1(1):65-74. doi:10. 3233/JPD-2011-001
136. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ, Frenk H (1993) Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. Brain Res 605:164-168
137. Maranis S, Stamatis D, Tsironis C, Konitsiotis S (2012) Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopainduced dyskinesia. Eur J Pharmacol 683(1-3):71-77. doi:10. 1016/j.ejphar.2012.02.036
138. Marino MJ, Williams DL Jr, O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG, Conn PJ (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA 100(23):13668-13673. doi:10.1073/pnas.1835724100
139. Marsden CD, Parkes JD (1997) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1(8007): 345-349
140. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM (2010) Memantine improves cognition and reduces Alzheimer'slike neuropathology in transgenic mice. Am J Pathol 176(2): 870-880. doi:10.2353/ajpath.2010.090452
141. Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T, Smith Y (2011) Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain 134(Pt 7):2057-2073. doi:10.1093/brain/awr137
142. Masuoka T, Mikami A, Kamei C (2010) Ameliorative effect of a hippocampal metabotropic glutamate receptor agonist on Histamine H1 receptor antagonist-induced memory deficit in rats. Journal of pharmacological sciences 113(1):41-47. doi:10.1254/jphs.10022FP
143. Matarredona ER, Santiago M, Venero JL, Cano J, Machado A (2001) Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP ? -induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 76(2):351-360
144. McCarthy DJ, Alexander R, Smith MA, Pathak S, Kanes S, Lee CM, Sanacora G (2012) Glutamate-based depression GBD. Med Hypotheses 78(5):675-681. doi:10.1016/j.mehy.2012.02.009
145. Medrik-Goldberg T, Lifschitz D, Pud D, Adler R, Eisenberg E (1999) Intravenous lidocaine, amantadine and placebo in the treatment of sciatica: a double-blind randomised controlled study. Reg Anesth Pain Med 24(6):534-540
146. Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 101(2):483-497. doi:10.1111/j.1471-4159.2007. 04456.x
147. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R (1999) Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 22(5):273-276
148. Messenger MJ, Dawson LG, Duty S (2002) Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract. Neuropharmacology 43(2):261-271
149. Moreau C, Delval A, Tiffreau V, Defebvre L, Dujardin K, Duhamel A, Petyt G, Hossein-Foucher C, Blum D, Sablonniere B, Schraen S, Allorge D, Destee A, Bordet R, Devos D (2013) Memantine for axial signs in Parkinson's disease: a randomised, doubleblind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 84(5):552-555. doi:10.1136/jnnp-2012-303182
150. Morel V, Etienne M, Wattiez A-S, Dupuis A, Privat A-M, Chalus M, Eschalier A, Daulhac L, Pickering G (2013) Memantine, a promising drug for the prevention o fneuropathic pain in rat. Eur J Pharmacol. doi:10.1016/j.ejphar.2013.06.020i. (Epub ahead of print)
151. Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58(7):981-986. doi:10.1016/j.neuropharm.2009. 12.024
152. Morin N, Grégoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T (2013a) MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 66:355-364. doi:10.1016/j.neu ropharm.2012.07.036
153. Morin N, Morissette M, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T (2013b) Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology 73C:216-231. doi:10.1016/j.neuropharm.2013. 05.028
154. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bedard PJ, Di Paolo T (2006) Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 21(1):9-17. doi:10.1002/mds.20654
155. Murray TK, Messenger MJ, Ward MA, Woodhouse S, Osborne DJ, Duty S, O'Neill MJ (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 73(2):455-466
156. Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, O'Neill MJ (2003) LY503430, a novel alpha-amino-3-hydroxy- 5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther 306(2):752-762. doi:10.1124/jpet.103.049445
157. Musazzi L, Treccani G, Mallei A, Popoli M (2013) The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol Psychiatry 73(12): 1180-1188. doi:10.1016/j.biopsych.2012.11.009
158. Nash JE, Hill MP, Brotchie JM (1999) Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpinetreated rat. Exp Neurol 155(1):42-48. doi:10.1006/exnr.1998. 6963
159. Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR (2000) Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 165(1):136-142. doi:10.1006/exnr.2000.7444
160. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM (2004) The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 188(2):471-479. doi:10.1016/j.expneurol. 2004.05.004
161. Nie H, Weng HR (2010) Impaired glial glutamate uptake induces extrasynaptic glutamate spillover in the spinal sensory synapses of neuropathic rats. J Neurophysiol 103(5):2570-2580. doi:10.1152/jn.00013.2010
162. Nishijima H, Arai A, Kimura T, Mori F, Yamada J, Migita K, Wakabayashi K, Baba M, Ueno S, Tomiyama M (2013) Drebrin immunoreactivity in the striatum of a rat model of levodopainduced dyskinesia. Neuropathology 33(4):391-396. doi:10. 1111/neup.12009
163. Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, Jamerson B, Menniti FS, Landen JW (2008) Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord 23(13):1860-1866. doi:10. 1002/mds.22169
164. Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, Rodriguez M (2008) Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 23(Suppl 3):S548-S559. doi:10.1002/mds.22062
165. Oh JD, Russell DS, Vaughan CL, Chase TN (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 813(1):150-159
166. Olanow CW (2007) The pathogenesis of cell death in Parkinson's disease. Mov Disord 22(Suppl 17):S335-S342. doi:10.1002/mds. 21675
167. Ondarza R, Velasco F, Velasco M, Aceves J, Flores G (1994) Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease. Stereotact Funct Neurosurg 62(1-4):90-97
168. O'Neill MJ, Murray TK, Whalley K, Ward MA, Hicks CA, Woodhouse S, Osborne DJ, Skolnick P (2004) Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur J Pharmacol 486(2):163-174. doi:10.1016/j.ejphar.2003.12.023
169. Ossola B, SchendzielorzN, Chen SH, Bird GS, Tuominen RK, Mannisto PT, Hong JS (2011) Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology 61(4):574-582. doi:10.1016/j.neuropharm.2011.04.030
170. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41(4):413-420
171. Ouattara B, Hoyer D, Gregoire L, Morissette M, Gasparini F, Gomez- Mancilla B, Di Paolo T (2010) Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 167(4):1160-1167. doi:10.1016/j.neuroscience.2010.03. 022
172. Ouattara B, Gregoire L, Morissette M, Gasparini F, Vranesic I, Bilbe G, Johns DR, Rajput A, Hornykiewicz O, Rajput AH, Gomez-Mancilla B, Di Paolo T (2011) Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 32(7):1286-1295. doi:10.1016/j.neurobiolaging.2009.07. 014
173. Palucha A, Klak K, Branski P, van der Putten H, Flor PJ, Pilc A (2007) Activation of the mGlu7 receptor elicits antidepressantlike effects in mice. Psychopharmacology 194(4):555-562. doi:10.1007/s00213-007-0856-2
174. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701(1-2):13-18
175. Paquette MA, Anderson AM, Lewis JR, Meshul CK, Johnson SW, Paul Berger S (2010) MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism. Neuropharmacology 58(7):1002-1008. doi:10. 1016/j.neuropharm.2010.01.003
176. Partosoedarso ER, Blackshaw LA (2000) Roles of central glutamate, acetylcholine and CGRP receptors in gastrointestinal afferent inputs to vagal preganglionic neurones. Auton Neurosci Basic Clin 83:37-48
177. Pawlak CR, Chen FS, Wu FY, Ho YJ (2012) Potential of Dcycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials. Kaohsiung J Med Sci 28(8):407-417. doi:10.1016/j.kjms.2012.02.010
178. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-Daspartate antagonist, CP-101,606, in patients with treatmentrefractory major depressive disorder. J Clin Psychopharmacol 28(6):631-637. doi:10.1097/JCP.0b013e31818a6cea
179. Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D (1998) The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 75:349-354
180. Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E (2012) Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and Entacapone. Clin Neuropharmacol 35(1):15-20. doi:10.1097/WNF.0b013e318241520b
181. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23(2):183-189; quiz 313. doi:10.1002/mds.21803
182. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-1341
183. Richards G, Messer J, Malherbe P, Pink R, Brockhaus M, Stadler H, Wichmann J, Schaffhauser H, Mutel V (2005) Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPgammas binding. J Comp Neurol 487(1):15-27. doi:10.1002/cne.20538
184. Rinne JO, Halonen T, Riekkinen PJ, Rinne UK (1988) Free amino acids in the brain of patients with Parkinson's disease. Neurosci Lett 94(1-2):182-186
185. Riquelme E, Abarca J, Campusano JM, Bustos G (2012) An NR2Bdependent decrease in the expression of trkB receptors precedes the disappearance of dopaminergic cells in substantia nigra in a rat model of presymptomatic Parkinson's disease. Parkinsons Dis 2012:129605. doi:10.1155/2012/129605
186. Rohof WO, Aronica E, Beaumont H, Troost D, Boeckxstaens GE (2012) Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study. Neurogastroenterol Motil 24(4):383-e173. doi:10.1111/j.1365-2982.2011.01868.x
187. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330(1):227-235. doi:10.1124/jpet.108.150425
188. Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA (2010) A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39(3):352-361. doi:10.1016/j.nbd.2010.05.001
189. Samadi P, Gregoire L, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bedard PJ, Di Paolo T (2008) mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 29(7):1040-1051. doi:10.1016/j. neurobiolaging.2007.02.005
190. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Herve D, Greengard P, Fisone G (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27(26):6995-7005. doi:10.1523/jneurosci.0852-07.2007
191. Santini E, Sgambato-Faure V, Li Q, Savasta M, Dovero S, Fisone G, Bezard E (2010) Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS ONE 5(8):e12322. doi:10.1371/journal.pone. 0012322
192. Schapira AH, Jenner P (2011) Etiology and pathogenesis of Parkinson's disease. Mov Disord 26(6):1049-1055. doi:10.1002/mds.23732
193. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54(3):823-827
194. Schmid S, Fendt M (2006) Effects of the mGluR8 agonist (S)-3,4- DCPG in the lateral amygdala on acquisition/expression of fearpotentiated startle, synaptic transmission, and plasticity. Neuropharmacology 50(2):154-164. doi:10.1016/j.neuropharm.2005. 08.002
195. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ (2003) LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6(3):189-197. doi:10.1080/102538 9031000146773
196. Schwartz TL, Siddiqui UA, Raza S (2012) Memantine as an augmentation therapy for anxiety disorders. Case Rep Psychiatry 2012:749796. doi:10.1155/2012/749796
197. Sgambato-Faure V, Cenci MA (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol 96(1):69-86. doi:10.1016/j.pneurobio. 2011.10.005
198. Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM (2005) Topiramate reduces levodopa-induced dyskinesia in the MPTPlesioned marmoset model of Parkinson's disease. Mov Disord 20(4):403-409. doi:10.1002/mds.20345
199. Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, Brotchie JM (2010) Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 64(2):177-180. doi:10.1002/syn.20739
200. Simmons RMA, Webster AA, Kalra AB, Iyengar S (2002) Group II mGluRreceptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav 73:419-427
201. Sivarao DV, Krowicki ZK, Abrahams TP, Hornby PJ (1999) Vagallyregulated gastric motor activity: evidence for kainate and NMDA receptor mediation. Eur J Pharmacol 368:173-182
202. Slawinska A, Wieronska JM, Stachowicz K, Palucha-Poniewiera A, Uberti MA, Bacolod MA, Doller D, Pilc A (2013) Anxiolyticbut not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu(4) receptor. Neuropharmacology 66:225-235. doi:10.1016/j.neuropharm. 2012.05.001
203. Sonsalla PK, Zeevalk GD, Manzino L, Giovanni A, Nicklas WJ (1992) MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4- phenylpyridinium in rats. J Neurochem 58(5):1979-1982
204. Sophie M, Ford B (2012) Management of pain in Parkinson's disease. CNS drugs 26(11):937-948. doi:10.1007/s40263-012-0005-2
205. Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT (2000) Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol 163(1):239-243. doi:10.1006/exnr.2000. 7374
206. Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C (2013) AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. doi:10.1002/mds.25561 Sukoff
207. Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL, Zhang MY, Di L, Platt BJ, Neal S, Dwyer JM, Bender CN, Zhang J, Lock T, Kowal D, Kramer A, Randall A, Huselton C, Vishwanathan K, Tse SY, Butera J, Ring RH, Rosenzweig-Lipson S, Hughes ZA, Dunlop J (2011) The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther 338(1): 345-352. doi:10.1124/jpet.110.177378
208. Suzuki R, Matthews EA, Dickenson AH (2001) Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy. Pain 91:101-109
209. Tamim MK, Samadi P, Morissette M, Gregoire L, Ouattara B, Levesque D, Rouillard C, Di Paolo T (2010) Effect of nondopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology 58(1):286-296. doi:10.1016/j.neuro pharm.2009.06.030
210. Tatarczyñska E, Palucha A, Szewczyk B, Chojnacka-Wójcik E, Wieroñska J, Pilc A (2002) Anxiolytic and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1- aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Pol J Pharmacol 54:707-710
211. Tatton WG, Chalmers-Redman R, Brown D, Tatton N (2003) Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 53 Suppl 3:S61-70. doi:10.1002/ana.10489 (discussion S70-62)
212. Truong L, Allbutt HN, Coster MJ, Kassiou M, Henderson JM (2009) Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA ? parafascicular lesions. Brain Res Bull 78(2-3):91-96. doi:10.1016/j.brainres bull.2008.10.004
213. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H (1991) Protection of substantia nigra from MPP? neurotoxicity by Nmethyl- D-aspartate antagonists. Nature 349(6308):414-418. doi:10.1038/349414a0
214. Ueda H, Ueda M (2009) Mechanisms underlying morphine analgesic tolerance and dependence. Front Biosci 14:5260-5272
215. Valenti O, Marino MJ, Wittmann M, Lis E, DiLella AG, Kinney GG, Conn PJ (2003) Group III metabotropic glutamate receptormediated modulation of the striatopallidal synapse. J Neurosci 23(18):7218-7226
216. Varanese S, Howard J, Di Rocco A (2010) NMDA antagonist memantine improves levodopa-induced dyskinesias and "onoff" phenomena in Parkinson's disease. Mov Disord 25(4):508-510. doi:10.1002/mds.22917
217. Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT (2005) Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci 22(7):1799-1806. doi:10.1111/j.1460-9568.2005.04362.x
218. Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A, Gasparini F, Spooren W, Stoehr N, Pagano A, Flor PJ, Vranesic I, Lingenhoehl K, Johnson EC, Varney M, Urban L, Kuhn R (2001) Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 40(1):1-9
219. Wang JQ, Arora A, Yang L, Parelkar NK, Zhang G, Liu X, Choe ES, Mao L (2005) Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity. Mol Neurobiol 32(3):237-249. doi:10. 1385/mn:32:3:237
220. Wang H, Jiang W, Yang R, Li Y (2011) Spinal metabotropic glutamate receptor 4 is involved in neuropathic pain. NeuroReport 22(5):244-248. doi:10.1097/WNR.0b013e3283453843
221. Warraich ST, Allbutt HN, Billing R, Radford J, Coster MJ, Kassiou M, Henderson JM (2009) Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Res Bull 78(2-3):85-90. doi:10.1016/j.brainresbull.2008.08.023
222. Wesseldijk F, Fekkes D, Huygen FJ, van de Heide-Mulder M, Zijlstra FJ (2008) Increased plasma glutamate, glycine, and arginine levels in complex regional pain syndrome type 1. Acta Anaesthesiol Scand 52(5):688-694. doi:10.1111/j.1399-6576. 2008.01638.x
223. Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemiparkinsonian rats. Neuropharmacology 47(2):184-194. doi:10. 1016/j.neuropharm.2004.03.011
224. Wierońska JM, Stachowicz K, Pałucha-Poniewiera A, Acher F, Brański P, Pilc A (2010) Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressantlike activity, mediated by serotonergic and GABAergic systems. Neuropharmacology 59(7-8):627-634. doi:10.1016/j.neuro pharm.2010.08.008
225. Willert RP, Woolf CJ, Hobson AR, Delaney C, Thompson DG, Aziz Q (2004) The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology 126(3):683-692. doi:10.1053/j.gas tro.2003.11.047
226. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 25(10):1357-1363. doi:10.1002/mds.23034
227. Wu HM, Tzeng NS, Qian L, Wei SJ, Hu X, Chen SH, Rawls SM, Flood P, Hong JS, Lu RB (2009) Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 34(10): 2344-2357. doi:10.1038/npp.2009.64
228. Yamamoto N, Soghomonian JJ (2009) Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by L-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience 163(4):1171-1180. doi:10.1016/j.neuroscience.2009.07.060
229. Yoshizumi M, Eisenach JC, Hayashida KI (2013) Valproate prevents dysregulation of spinal glutamate and reduces the development of hypersensitivity in rats after peripheral nerve injury. J Pain Off J Am Pain Soc. doi:10.1016/j.jpain.2013.07.007
230. Young RL, Cooper NJ, Blackshaw LA (2008) Anatomy and function of group III metabotropic glutamate receptors in gastric vagal pathways. Neuropharmacology 54(6):965-975. doi:10.1016/j. neuropharm.2008.02.010
231. Zammataro M, Chiechio S, Montana MC, Traficante A, Copani A, Nicoletti F, Gereau RW (2011) mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists. Mol Pain 7:6. doi:10.1186/1744-8069-7-6
232. Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA (2013) A randomized trial of a low-trapping nonselective N methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74(4):257-264. doi:10.1016/j.biopsych.2012.10.019
233. Zerbib F, Bruley des Varannes S, Roman S, Tutuian R, Galmiche JP, Mion F, Tack J, Malfertheiner P, Keywood C (2011) Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 33(8):911-921. doi:10.1111/j.1365-2036.2011.04596.x
234. Zhang X, Fogel R (2003) Involvement of glutamate in gastrointestinal vago-vagal reflexes initiated by gastrointestinal distention in the rat. Auton Neurosci Basic Clin 103:19-37
235. Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch JJ 3rd, Wade CL, Decker MW, Honore P (2004) Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 506(2):107-118. doi:10.1016/j. ejphar.2004.11.005
236. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU (1992a) MK-801 prevents 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine- induced Parkinsonism in primates. J Neurochem 59:733-739
237. Zuddas A, Vaglini F, Fornai F, Fascetti F, Saginario A, Corsini GU (1992b) Pharmacologic modulation of MPTP toxicity: MK 801 in prevention of dopaminergic cell death in monkeys and mice. Ann N Y Acad Sci 648:268-271